In recent years, the therapeutic footprint of this class has grown: long-acting agents (e.g., liraglutide, semaglutide) and next-generation dual/triple agonists (e.g., tirzepatide) have demonstrated superior glycemic control, weight reduction, and cardiovascular benefits in adults with T2DM (Yao et al., 2024)
Clinical indications include clinical history, symptoms and biomarkers that may help guide personalisation
Common examples include semaglutide, liraglutide, and dulaglutide
Schneeweiss is participating in investigator-initiated grants to the Brigham and Womens Hospital from Boehringer Ingelheim, Takeda, and UCB unrelated to the topic of this study
and lower fluid intake means a drier result